Eric Garner Named OSRX Chief Commercial Officer

Rapid climb up executive ranks lands Garner at helm of all sales and marketing efforts for ophthalmic compounder

MANHATTAN BEACH, Calif. (May 7, 2021) – Since joining pharmaceutical startup OSRX® in March 2019 as director of marketing, Eric Garner has quickly ascended the corporate ladder. He was named vice president of marketing in January 2020 and was just promoted again, becoming chief commercial officer for OSRX. The newly formed position places Garner in charge of the marketing and sales departments for a burgeoning organization that compounds solutions for post-op cataract and refractive procedures, glaucoma management and myopia control.

“Eric’s strategic problem-solving skills are extraordinary,” says OSRX Founder and CEO Anthony Sampietro.  “He’s always accountable – a tactical implementer who takes the initiative to identify opportunities that improve the organization. Most people sit back and wait to be told what to do. Eric comes to me with strategic plans and solutions and makes things happen.”

During his tenure at OSRX, Garner has led corporate branding efforts, helped introduce the OSRX compounding pharmacy and implemented national public relations, marketing and digital ad campaigns. As chief commercial officer, Garner, 33, will be responsible for everything from sales strategy, sales force automation initiatives and customer service to national strategic marketing/communications plans and implementation.

“Eric’s ability to harness and maximize the opportunities afforded in the digital age is amazing,” says Sampietro. “This will help him blend all of our disparate sales and marketing responsibilities into one cohesive commercial strategy. 

“Despite all the COVID challenges presented in 2020, OSRX exceeded annual revenue for the fourth consecutive year and we saw our first year of profitability.  I’m confident our fortified commercial strategy will help us achieve top-line revenue for the foreseeable future. Eric certainly has all the tools to guide this commercial and product expansion into our next chapter of growth.”

For more information, visit

OSRX is a PCAB-accredited 503A compounding pharmacy based in Missoula, Mont., that formulates customized ophthalmic medications for surgical vision correction, myopia control and glaucoma management. Our OMNI compounded medications provide your patients with personalized drop care plans with a simple dosing regimen that reduces barriers to use and promotes easy adherence. OSRX is an affiliate of Southern California-based biotech firm Ocular Science®. Learn more at or email us at

OSRX operates in compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.